Preventive Measures for Immunocompromised Patients

AstraZeneca’s Evusheld™ (tixagevimab and cilgavimab) is an investigational medicine that has emergency use authorization (EUA) by the U.S. Food and Drug Administration (FDA).

Evusheld is a monoclonal antibody designed to provide additional immunity and prevent COVID-19 in individuals 12 years of age or older who are moderately to severely immunocompromised. These individuals may not be able to generate a strong enough immune response from the COVID-19 vaccine, making them vulnerable to severe illness. Evusheld may also be used in individuals who are not able to receive the available COVID-19 vaccines due to a history of severe adverse reaction.

Please note:

  • Evusheld is not a substitute for getting vaccinated in patients who are able to do so.
  • Evusheld is not currently indicated for early treatment of COVID-19 or to prevent infection after being exposed.

How is Evusheld given?

Evusheld consists of 2 monoclonal antibodies which are given as two separate injections in the buttocks, one after the other in the same visit. Patients will be monitored for one hour afterward for any side effects.

Who is eligible for Evusheld?

Evusheld is designed to be given to individuals who are moderately to severely immunocompromised due to a medical condition or who take an immunosuppressive medication. These individuals are less likely to mount an immune response to vaccination or natural infection. They also have a higher risk of severe disease.

Evusheld is also available to individuals who are unable to receive the COVID-19 vaccine due to a history of a severe reaction, as determined by assessment by an allergist and immunologist.

There is an extremely limited supply of Evusheld, which prevents us from being able to offer this medication to everyone who may be eligible at this point in time. As a result of this limited supply, Dartmouth-Hitchcock Health (D-HH) will be identifying those patients who are most vulnerable to severe illness based on their risk of complications from COVID-19. We will offer Evusheld to the most vulnerable patients first and we will continue to provide it in the weeks and months ahead.

How will patients know that they qualify and when can they get treatment?

If you are immunocompromised and would like to be considered for Evusheld, please contact your provider. Your provider will then submit a referral for you, which will put you on a list of eligible patients.

Please note that it will likely take months until most eligible patients are able to receive this therapy due to limited supplies. D-HH will contact all qualifying patients as soon as possible so there is no need to follow up again with your provider. We are committed to making this an equitable process for patient who will benefit from this drug.

Additional information about Evusheld is provided on their Fact Sheet for Patients, Parents and Caregivers (PDF).